|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.06 USD | -0.79% |
|
-5.45% | -50.59% |
| 07-22 | Keros Therapeutics, Inc. Announces CFO Changes | CI |
| 07-22 | Keros Therapeutics, Inc. Announces Appointment of Annita Tanini as Interim Principal Accounting Officer, Effective August 4, 2026 | CI |
Company Valuation: Keros Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,369 | 1,323 | 1,191 | 641.2 | 620.3 | 199.1 | - | - |
| Change | - | -3.39% | -9.94% | -46.17% | -3.27% | -67.9% | - | - |
| Enterprise Value (EV) | 1,369 | 1,323 | 860 | 81.3 | 620.3 | 199.1 | 199.1 | 199.1 |
| Change | - | -3.39% | -34.98% | -90.55% | 662.95% | -67.9% | 0% | 0% |
| P/E | -23.2x | -11.6x | -7.65x | -3.17x | 8.85x | -1.68x | -1.84x | -2.47x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.82x | -0x | 0x | 0.21x | 0.1x |
| Capitalization / Revenue | 68.1x | - | 7,889x | 181x | 2.54x | 46.8x | 10.5x | 3.53x |
| EV / Revenue | 0x | - | 0.01x | 0x | 0x | 46.8x | 10.5x | 3.53x |
| EV / EBITDA | - | - | -0x | -0x | 0x | -1.58x | -2.24x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -1.54x | -1.39x | -1.54x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -2.12x | -1.86x | -1.95x |
| FCF Yield | -4.61% | -5.39% | -10.7% | -25.3% | 17.1% | -47.2% | -53.7% | -51.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.52 | -4.15 | -5.2 | -5 | 2.3 | -5.998 | -5.46 | -4.074 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 20.1 | - | 0.151 | 3.55 | 244.1 | 4.252 | 18.91 | 56.45 |
| EBITDA 1 | - | - | -169.1 | -209.6 | 69.08 | -125.8 | -89.01 | - |
| EBIT 1 | -56.37 | -114.8 | -169.9 | -210.8 | 67.57 | -129.6 | -143 | -129.7 |
| Net income 1 | -58.74 | -104.7 | -153 | -187.4 | 87.01 | -120.5 | -132 | -110.4 |
| Net Debt | - | - | -331.1 | -559.9 | - | - | - | - |
| Reference price 2 | 58.51 | 48.02 | 39.76 | 15.83 | 20.36 | 10.06 | 10.06 | 10.06 |
| Nbr of stocks (in thousands) | 23,399 | 27,543 | 29,959 | 40,507 | 30,466 | 19,792 | - | - |
| Announcement Date | 3/9/22 | 3/3/23 | 2/28/24 | 2/26/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.68x | - | - | -.--% | 199M | |
| 33.56x | 8.36x | 25.84x | 0.05% | 57.28B | |
| 20.68x | 6.37x | 13.94x | 1.54% | 54.99B | |
| -41.86x | 13.29x | -39.17x | -.--% | 23.18B | |
| -17.88x | 4.15x | -7.26x | -.--% | 22.59B | |
| 25.74x | 5.04x | 13.35x | -.--% | 20.46B | |
| 24.54x | 4.77x | 15.5x | -.--% | 17.56B | |
| -523.64x | 37.41x | -1539.29x | -.--% | 15.67B | |
| 43.58x | 17.61x | 45.34x | 0.08% | 14.46B | |
| 17.42x | 5.04x | 11.77x | -.--% | 13.92B | |
| Average | -41.95x | 11.34x | -162.22x | 0.17% | 24.03B | |
| Weighted average by Cap. | -19.51x | 9.70x | -89.86x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- KROS Stock
- Valuation Keros Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
